Exploration of the Correlation Between GRHL1 Expression and Tumor Microenvironment in Endometrial Cancer and Immunotherapy

References

• Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110(4):354–361. doi:10.1093/jnci/djx214
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Huo X, Sun H, Liu Q, et al. Clinical and expression significance of AKT1 by co-expression network analysis in endometrial cancer. Front Oncol. 2019;9:1147. doi:10.3389/fonc.2019.01147
   PubMed Web of Science ®Google Scholar
• Chambers LM, Carr C, Freeman L, Jernigan AM, Michener CM. Does surgical platform impact recurrence and survival? A study of utilization of multiport, single-port, and robotic-assisted laparoscopy in endometrial cancer surgery. Am J Obstet Gynecol. 2019;221(3):243 e241–243 e211. doi:10.1016/j.ajog.2019.04.038
   Web of Science ®Google Scholar
• Wright JD, Khoury-Collado F, Melamed A. Harnessing minimally invasive surgery to improve outcomes in endometrial cancer surgery-the robots are coming. JAMA Surg. 2019;154(6):539. doi:10.1001/jamasurg.2018.5841
   PubMed Web of Science ®Google Scholar
• Aoki Y, Kanao H, Wang X, et al. Adjuvant treatment of endometrial cancer today. Jpn J Clin Oncol. 2020;50(7):753–765. doi:10.1093/jjco/hyaa071
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin Oncol. 2017;35(22):2535–2541. doi:10.1200/JCO.2017.72.5952
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 2019;20(5):711–718. doi:10.1016/S1470-2045(19)30020-8
   PubMed Web of Science ®Google Scholar
• Darido C, Georgy SR, Wilanowski T, et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell. 2011;20(5):635–648. doi:10.1016/j.ccr.2011.10.014
   PubMed Web of Science ®Google Scholar
• Georgy SR, Cangkrama M, Srivastava S, et al. Identification of a novel proto-oncogenic network in head and neck squamous cell carcinoma. J Natl Cancer Inst. 2015;107(9). doi:10.1093/jnci/djv152
   PubMedGoogle Scholar
• Bhandari A, Gordon W, Dizon D, et al. The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1. Oncogene. 2013;32(12):1497–1507. doi:10.1038/onc.2012.168
   PubMed Web of Science ®Google Scholar
• Werner S, Frey S, Riethdorf S, et al. Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem. 2013;288(32):22993–23008. doi:10.1074/jbc.M113.456293
   PubMed Web of Science ®Google Scholar
• Quan Y, Xu M, Cui P, Ye M, Zhuang B, Min Z. Grainyhead-like 2 promotes tumor growth and is associated with poor prognosis in colorectal cancer. J Cancer. 2015;6(4):342–350. doi:10.7150/jca.10969
   PubMed Web of Science ®Google Scholar
• Gasperoni JG, Fuller JN, Darido C, Wilanowski T, Dworkin S. Grainyhead-like (Grhl) target genes in development and cancer. Int J Mol Sci. 2022;23(5):2735. doi:10.3390/ijms23052735
   PubMed Web of Science ®Google Scholar
• Kotarba G, Taracha-Wisniewska A, Wilanowski T. Grainyhead-like transcription factors in cancer - Focus on recent developments. Exp Biol Med. 2020;245(5):402–410. doi:10.1177/1535370220903009
   Web of Science ®Google Scholar
• Fabian J, Lodrini M, Oehme I, et al. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res. 2014;74(9):2604–2616. doi:10.1158/0008-5472.CAN-13-1904
   PubMed Web of Science ®Google Scholar
• Li M, Li Z, Guan X, Qin Y. Suppressor gene GRHL1 is associated with prognosis in patients with oesophageal squamous cell carcinoma. Oncol Lett. 2019;17(5):4313–4320. doi:10.3892/ol.2019.10072
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. doi:10.1093/nar/gkv1507
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Xu L, Deng C, Pang B, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575–6580. doi:10.1158/0008-5472.CAN-18-0689
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34. doi:10.1186/s13073-019-0638-6
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Prior FW, Clark K, Commean P, et al. TCIA: an information resource to enable open science. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:1282–1285. doi:10.1109/EMBC.2013.6609742
   PubMedGoogle Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6(1):7458. doi:10.1038/ncomms8458
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
   PubMed Web of Science ®Google Scholar
• Garris CS, Luke JJ. Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res. 2020;26(15):3901–3907. doi:10.1158/1078-0432.CCR-19-1321
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53. doi:10.1186/s12943-020-01170-0
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi:10.1016/S0140-6736(15)00130-0
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Chambers SK. Advances in chemotherapy and targeted therapies in endometrial cancer. Cancers. 2022;14(20):5020. doi:10.3390/cancers14205020
   PubMed Web of Science ®Google Scholar
• Mahdi H, Chelariu-Raicu A, Slomovitz BM. Immunotherapy in endometrial cancer. Int J Gynecol Cancer. 2023;33(3):351–357. doi:10.1136/ijgc-2022-003675
   PubMed Web of Science ®Google Scholar
• Mathiyalagan N, Miles LB, Anderson PJ, et al. Meta-analysis of grainyhead-like dependent transcriptional networks: a roadmap for identifying novel conserved genetic pathways. Genes. 2019;10(11):876. doi:10.3390/genes10110876
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Cottle DL, Tan FH, et al. Loss of GRHL3 leads to TARC/CCL17-mediated keratinocyte proliferation in the epidermis. Cell Death Dis. 2018;9(11):1072. doi:10.1038/s41419-018-0901-6
   PubMedGoogle Scholar
• Xu H, Liu C, Zhao Z, et al. Clinical implications of GRHL3 protein expression in breast cancer. Tumour Biol. 2014;35(3):1827–1831. doi:10.1007/s13277-013-1244-7
   PubMedGoogle Scholar
• Pifer PM, Farris JC, Thomas AL, et al. Grainyhead-like 2 inhibits the coactivator p300, suppressing tubulogenesis and the epithelial-mesenchymal transition. Mol Biol Cell. 2016;27(15):2479–2492. doi:10.1091/mbc.e16-04-0249
   PubMed Web of Science ®Google Scholar
• Chung VY, Tan TZ, Tan M, et al. GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci Rep. 2016;6(1):19943. doi:10.1038/srep19943
   PubMedGoogle Scholar
• Mlacki M, Darido C, Jane SM, Wilanowski T. Loss of Grainy head-like 1 is associated with disruption of the epidermal barrier and squamous cell carcinoma of the skin. PLoS One. 2014;9(2):e89247. doi:10.1371/journal.pone.0089247
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z
   PubMed Web of Science ®Google Scholar
• Kaderbhai C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers. 2019;11(2):201. doi:10.3390/cancers11020201
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–326. doi:10.1016/j.cell.2018.09.035
   PubMed Web of Science ®Google Scholar
• Yang Z, Wei S, Deng Y, Wang Z, Liu L. Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. Jpn J Clin Oncol. 2020;50(9):1023–1031. doi:10.1093/jjco/hyaa076
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi:10.1038/bjc.2015.190
   PubMed Web of Science ®Google Scholar